(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
Vote In favor of Your Favored Sort Of Dress - 2'Harmonious' meeting between Merz, Lula despite Belém controversy
- 3Nations for Rock Climbing
- 4The Best Internet Mastering Stages for Expertise Improvement
- 5‘Everybody Loves Raymond: 30th Anniversary Reunion’ premiere date: How to watch, channel, time, cast and more
- Opening Inventiveness: Rousing Thoughts and Undertakings
- Vote In favor of Your Favored Kind Of Tea
- Manual for Tracking down Financial plan Amicable Travel Objections
- Improving as a Cook: Culinary Experiences in the Kitchen
- The Secret Side of Italy: 12 Underrated Destinations Locals Don’t Want Tourists to Find
- Trial of pro-Palestine activist begins
- Full SNAP benefits must be paid ‘promptly,’ USDA tells states as government reopens
- Banks for High Fixed Store Rates: Augment Your Investment funds
- Watch Blue Origin's huge New Glenn rocket ace its epic landing on a ship at sea (video)
